Peptides

SS-31 (Elamipretide) Research Overview

Research overview of SS-31 (elamipretide), a mitochondrial-targeted peptide studied for cardiac, renal, and mitochondrial membrane stabilisation research.

SS-31 (also known as elamipretide or MTP-131) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively target and stabilise mitochondrial membranes. Developed by Hazel Szeto and colleagues, SS-31 represents a novel approach to addressing mitochondrial dysfunction - a common feature of many age-related conditions and diseases. Researchers have observed protective effects across multiple organ systems in preclinical and early clinical studies.

Mechanism of Action

Mitochondrial Targeting

SS-31’s design incorporates several features that enable selective mitochondrial accumulation:

  • The positively charged lysine and arginine residues drive uptake into mitochondria in response to the membrane potential (typically -180 mV)
  • The dimethyltyrosine (Dmt) residue provides antioxidant activity
  • The peptide accumulates selectively in the inner mitochondrial membrane, reaching concentrations estimated to be 1000-5000 fold higher than in the cytoplasm
  • This targeting is independent of mitochondrial membrane potential collapse, distinguishing it from some other mitochondrial-targeting strategies

Cardiolipin Interaction

The primary molecular target of SS-31 is cardiolipin, a phospholipid unique to the inner mitochondrial membrane:

  • Cardiolipin is essential for the structural integrity of the inner mitochondrial membrane
  • It plays critical roles in the organisation of the electron transport chain complexes
  • Cardiolipin is required for optimal function of cytochrome c, complex III, and complex IV
  • Under pathological conditions, cardiolipin can become oxidised, leading to mitochondrial dysfunction

Researchers have observed that SS-31 binds to cardiolipin and:

  • Protects cardiolipin from oxidation
  • Maintains the cristae structure of the inner mitochondrial membrane
  • Preserves the organisation of electron transport chain supercomplexes
  • Prevents cytochrome c release (a trigger for apoptosis)

Electron Transport Chain Support

Through its cardiolipin-stabilising effects, SS-31 appears to support electron transport chain function:

  • Researchers have observed improved efficiency of oxidative phosphorylation
  • Reduced electron leakage and consequent reduction in reactive oxygen species (ROS) production
  • Maintenance of ATP synthesis under conditions of metabolic stress

Antioxidant Activity

Beyond its indirect effects through mitochondrial stabilisation, SS-31 possesses direct antioxidant properties:

  • The Dmt residue can scavenge hydrogen peroxide and peroxynitrite
  • The peptide does not interfere with physiological ROS signalling (unlike broad-spectrum antioxidants)
  • Researchers have observed selective reduction of excessive ROS without suppressing normal redox signalling

Key Research

Cardiac Research

Cardiac tissue has a high mitochondrial density and is particularly sensitive to mitochondrial dysfunction, making it a primary focus of SS-31 research:

  • Ischaemia-reperfusion injury: Researchers have observed that SS-31 reduces infarct size and preserves cardiac function in animal models of myocardial infarction
  • Heart failure: Preclinical studies in models of heart failure have reported improved cardiac function and reduced remodelling with SS-31 treatment
  • Cardioprotection: Animal studies suggest SS-31 may protect against doxorubicin-induced cardiotoxicity, a significant clinical concern in cancer chemotherapy
  • Aged hearts: Research in aged animal models has shown improvements in cardiac function, suggesting potential relevance to age-related cardiac decline

Renal Research

The kidney, with its high energy demands, is another organ system where SS-31 has shown preclinical promise:

  • Acute kidney injury: Researchers have observed protective effects in animal models of ischaemic and nephrotoxic acute kidney injury
  • Chronic kidney disease: Preclinical data suggests SS-31 may slow the progression of kidney fibrosis
  • Diabetic nephropathy: Some research has examined SS-31’s effects on kidney damage associated with diabetes

Skeletal Muscle

Research into skeletal muscle has examined SS-31’s effects on age-related muscle decline:

  • Researchers have observed improved mitochondrial function and exercise capacity in aged animals treated with SS-31
  • Muscle fatigue resistance appeared to improve in preclinical studies
  • Effects on mitochondrial biogenesis markers have been reported

Neurological Research

Emerging research has explored SS-31 in neurological contexts:

  • Animal models of neurodegenerative disease have shown some protective effects
  • Research into age-related cognitive decline has been conducted
  • These findings are in early preclinical stages

Clinical Trials

Early-phase clinical trials have been conducted with elamipretide:

  • Phase 1/2 studies: Safety and pharmacokinetic data have been collected
  • Barth syndrome: Clinical trials in this rare mitochondrial disease have been conducted
  • Age-related macular degeneration: Research into retinal mitochondrial dysfunction has been pursued
  • Primary mitochondrial myopathy: Clinical trials have examined elamipretide in this condition

Australian Research Context

SS-31/elamipretide is not approved by the TGA and is not listed on the Australian Register of Therapeutic Goods (ARTG). As an investigational compound, it remains in the research and clinical trial phase globally.

Researchers interested in SS-31 should note that the existing evidence base consists of a combination of preclinical studies and early-phase clinical trials. The compound has not yet received regulatory approval in any major market.

Research Limitations

Important considerations in the SS-31 research landscape:

  • While preclinical results are promising, Phase 3 clinical trial results are still pending or have shown mixed results
  • The translation from animal models of mitochondrial dysfunction to human disease conditions is complex
  • Optimal dosing, treatment duration, and patient selection criteria are still being refined
  • Long-term safety data is limited
  • The specificity of mitochondrial targeting in different tissue contexts requires further characterisation
  • Some clinical trials have not met their primary endpoints, tempering initial enthusiasm
  • MOTS-c - A mitochondrial-derived peptide studied in metabolic and exercise research
  • GHK-Cu - A copper peptide with tissue repair and antioxidant research
  • BPC-157 - A pentadecapeptide with cytoprotective research
  • GLP-1 Peptides - Overview of GLP-1 receptor agonist research

For research literacy and educational purposes only. This content does not constitute medical advice or therapeutic recommendation. Consult a qualified healthcare professional for medical decisions.